Drug intelligence / Profile preview

ramipril + atenolol + hydrochlorothiazide

Development stage
Unknown
Lead developer
Cadila Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

This is a fixed-dose combination drug containing three active pharmaceutical ingredients: ramipril, atenolol, and hydrochlorothiazide. Ramipril is an angiotensin-converting enzyme (ACE) inhibitor that relaxes blood vessels by inhibiting the conversion of angiotensin I to angiotensin II, thereby lowering blood pressure. Atenolol is a beta-1 adrenergic receptor antagonist (beta-blocker) that reduces heart rate and cardiac output, further contributing to antihypertensive effects. Hydrochlorothiazide is a thiazide diuretic that promotes the excretion of sodium and water from the kidneys, reducing blood volume and thus lowering blood pressure. This combination targets multiple mechanisms involved in hypertension management and may be used for patients requiring more than one agent for adequate control[5][6]. The primary indication is essential hypertension.

Brand names
PolycapPolypill - Cadila PharmaceuticalsQuintapill
Other names
aspirin/atenolol/hydrochlorothiazide/ramipril/simvastatin
02

Targets

ACE (Angiotensin Converting Enzyme)ADRB1 (β1)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)

Beyond the preview

Go deeper on ramipril + atenolol + hydrochlorothiazide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ramipril + atenolol + hydrochlorothiazide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call